Amended Quarterly Report (10-q/a)
October 20 2021 - 4:38PM
Edgar (US Regulatory)
0001601280
true
12/31
2021
Q2
0001601280
2021-01-01
2021-06-30
0001601280
2021-09-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
or
¨ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______________________to__________________________
Commission File Number: 333-194337
MediXall Group, Inc.
(Exact name of registrant as specified in its
charter)
Nevada
|
33-0864127
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification Number)
|
|
|
2929 East Commercial Blvd., PH-D,
Ft. Lauderdale, Florida
|
33308
|
(Address of principal executive offices)
|
(Zip Code)
|
954-440-4678
(Registrant’s telephone number, including area
code)
Not applicable
(Former name, former address and former fiscal
year, if changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ¨
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes ☒ No ¨
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions
of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging
growth company” in Rule 12b-2 of the Exchange Act.
|
|
Large accelerated filer ¨
|
Accelerated filer ¨
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
|
Emerging growth company ¨
|
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ☒
As of September 30, 2021, the issuer had 106,148,845 shares
of its common stock issued and outstanding.
Explanatory Note
This Amendment No. 1 (“Amendment No. 1”) to the Quarterly Report
on Form 10-Q of MediXall Group, Inc. (the “Company”) for the quarter ended June 30, 2021, originally filed with the Securities
and Exchange Commission on September 30, 2021 (the “Original Filing”), is being filed solely to correct an error on the cover
page to the Original Filing. The Original Filing inadvertently checked the “Yes” box to indicate that it was a shell company.
Amendment No. 1 amends and restates the cover page to the Original Filing to indicate that the Company is not a shell company by checking
the “No” box appearing after the following statement “Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act)”.
In addition to the change described above, Part II, Item 6 (Exhibits) is
hereby amended to reference certifications of the Company’s Chief Executive Officer and Chief Financial Officer as required by Section
302 of the Sarbanes-Oxley Act of 2002. These certifications are filed as Exhibits 31.1 and 31.2 to Amendment No. 1.
Except as described above, no other changes have been made to the Original
Filing, and Amendment No. 1 does not modify, amend or update in any way any of the financial or other information contained in the Original
Filing. Amendment No. 1 does not reflect events that may have occurred subsequent to the filing date of the Original Filing.
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS.
———————
(1) Filed herewith.
(2) Previously furnished.
(3) Previously filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
MediXall Group, Inc.
|
|
|
|
Dated: October 20, 2021
|
By:
|
/s/ Timothy S. Hart
|
|
|
Timothy S. Hart
|
|
|
Chief Financial Officer (Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
Dated: October 20, 2021
|
By:
|
/s/ Neil Swartz
|
|
|
Neil Swartz
|
|
|
Interim Chief Executive Officer (Principal Executive Officer)
|
MediXall (CE) (USOTC:MDXL)
Historical Stock Chart
From Jul 2024 to Aug 2024
MediXall (CE) (USOTC:MDXL)
Historical Stock Chart
From Aug 2023 to Aug 2024